Clostridium Difficile News and Research

RSS
Clostridium difficile is a type of bacterium found in human and animal waste. Clostridium difficile is a common cause of diarrhea that occurs in hospitals. It can also cause diarrhea or other intestinal disorders in patients treated with antibiotics.
TRU-D SmartUVC’s Ebola-killing UVC automated disinfection robot to be showcased at IDWeek 2014

TRU-D SmartUVC’s Ebola-killing UVC automated disinfection robot to be showcased at IDWeek 2014

Researchers reveal 'programmable' antibiotic technique to target drug-resistant microbes

Researchers reveal 'programmable' antibiotic technique to target drug-resistant microbes

Fecal microbiota transplantation officially recommended for effective treatment of C. difficile infection

Fecal microbiota transplantation officially recommended for effective treatment of C. difficile infection

C Diff Foundation to present 2014 "Raising C.difficile Awareness" conference in November

C Diff Foundation to present 2014 "Raising C.difficile Awareness" conference in November

Synthetic Biologics' SYN-005 antibody gets FDA Orphan Drug designation for Pertussis treatment

Synthetic Biologics' SYN-005 antibody gets FDA Orphan Drug designation for Pertussis treatment

Widespread use of unnecessary antibiotics drives up avoidable healthcare costs

Widespread use of unnecessary antibiotics drives up avoidable healthcare costs

Antibiotic stewardship programs reduce hospital readmissions due to infection

Antibiotic stewardship programs reduce hospital readmissions due to infection

Synthetic announces positive results from final preclinical toxicology study of SYN-004

Synthetic announces positive results from final preclinical toxicology study of SYN-004

University of Leicester research sniffs out smell of disease in feces

University of Leicester research sniffs out smell of disease in feces

Synthetic Biologics hosts Investor Day to discuss irritable bowel syndrome program

Synthetic Biologics hosts Investor Day to discuss irritable bowel syndrome program

Synthetic Biologics' SYN-005 antibody for Pertussis treatment to be highlighted at ICAAC 2014

Synthetic Biologics' SYN-005 antibody for Pertussis treatment to be highlighted at ICAAC 2014

Inovio Pharmaceuticals reports increased revenue in second quarter 2014

Inovio Pharmaceuticals reports increased revenue in second quarter 2014

Johns Hopkins Medicine, Kaiser Permanente partner to expand ways to deliver quality care

Johns Hopkins Medicine, Kaiser Permanente partner to expand ways to deliver quality care

Expert guidance offers recommendations for hand hygiene in healthcare facilities

Expert guidance offers recommendations for hand hygiene in healthcare facilities

NIAID launches CRS3123 Phase I trial to treat C. difficile infection

NIAID launches CRS3123 Phase I trial to treat C. difficile infection

Fecal transplantation safe, effective for treating C. difficile in immunocompromised patients

Fecal transplantation safe, effective for treating C. difficile in immunocompromised patients

Antibiotic treatment for patients who underwent gall bladder removal does not reduce infection risk

Antibiotic treatment for patients who underwent gall bladder removal does not reduce infection risk

Covenant and Sartori medical centers deploy TRU-D SmartUVC superbug-slaying robot

Covenant and Sartori medical centers deploy TRU-D SmartUVC superbug-slaying robot

Synthetic Biologics supports SYN-004 C.difficile preventative program with formation of Clinical Advisory Board

Synthetic Biologics supports SYN-004 C.difficile preventative program with formation of Clinical Advisory Board

Preventing antibiotic side effects: an interview with Florence Séjourné, CEO, Da Volterra

Preventing antibiotic side effects: an interview with Florence Séjourné, CEO, Da Volterra